The Effect of Finerenone on SII, PLR, NLR, MLR, NHR, and SIRI in Patients with Type 2 Diabetic Nephropathy

Abstract

Objective: To discuss and analyze the effects of routine therapy combined with fenethisterone on serum systemic immune inflammation index (SII), platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), neutrophil to high density lipoprotein ratio io, NHR) and Systemic Inflammation Response Index (SIRI). Methods: 60 patients with type 2 diabetes nephropathy admitted to our hospital from April to August 2020 were studied, including 20 patients with normal urinary protein, 20 patients with microalbuminuria and 20 patients with massive proteinuria. Patients with different proteinuria conditions were randomly divided into a control group and an experimental group, with 10 cases in each group. The control group received conventional therapy, while the experimental group received combined treatment with non nifedipine. Analyze and compare the changes in SII, PLR, NLR, MLR, NHR, and SIRI indicators between two groups of patients after intervention. Results: The serum SII, PLR, NLR, MLR, NHR, SIRI in patients with type 2 diabetes nephropathy with normal urinary protein, microalbumin and large proteinuria who were treated with fenelidone were significantly reduced, p < 0.05, The difference is significant. Conclusion: The combination of conventional therapy and fenelidone can effectively improve the immune function of patients with type 2 diabetes nephropathy and reduce the inflammatory reaction of the body. It is an effective therapeutic drug and can be used in such patients.